Navigation Links
American College of Medical Genetics responds to new FDA labeling decision for warfarin
Date:8/23/2007

BETHESDA, MD August 23, 2007 On August 16, the Food and Drug Administration approved new labeling information for the blood-thinner warfarin, sold under the brand name Coumadin. The new label suggests that one can prescribe higher or lower doses that may be safer for patients with variations in two genes, CYP2C9 or VKORC1. These variations can be learned through genetic testing, which may be a useful tool in determining appropriate dosing levels for individual patients and lower risks of bleeding complications.

The FDA labeling change for warfarin is the next step in the pathway toward incorporating genetics into the care of patients who need anticoagulation. The FDA has said that physicians should be aware of the role of genetics in warfarin dosing, but now the hard part is doing the necessary groundwork to determine how best to use genetic testing to improve care, said Marc S. Williams, MD, FACMG, ACMG Board Member and a co-chair of the expert group on Pharmacogenetic Testing of CYP2C9 and VKORC1 Alleles for Warfarin Use. This group is completing a report on the use of pharmacogenomic testing for warfarin and is based on a rapid-ACCE (Analytic validity, Clinical validity, Clinical utility and Ethical, legal and social implications) Review on Genetic Testing and Warfarin Dosing.

Available online at www.acmg.net, this 74-page report is the most thorough review of the scientific and clinical evidence surrounding the use of genetic testing to guide dosing of warfarin and was undertaken by a multidisciplinary group convened in 2006 of clinical pharmacologists, doctors of pharmacy, clinical geneticists, physicians with expertise in the use of warfarin, pharmacoeconomists, and experts in evidence-based medicine. The purpose of the rapid-ACCE review was to provide an independent, systematic review of the evidence and to develop recommendations based on this evidence. The review indicated that the test itself i
'/>"/>

Contact: Kathy Beal
kbeal@acmg.net
301-238-4582
American College of Medical Genetics
Source:Eurekalert

Page: 1 2

Related biology news :

1. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
2. Health costs soar as 60 million Americans classed as obese
3. Discovery of an American salamander where it shouldnt be: Korea
4. DNA traces evolution of extinct sabertooths and the American cheetah-like cat
5. North & South American researchers find architectural abnormalities in T. cruzi ribosome
6. T-rays: New imaging technology spotlighted by American Chemical Society
7. New peptide antibiotic isolated from American oyster
8. Computers to save unique type of American red squirrel
9. Alcoholism, smoking and genetics among Plains American Indians
10. Gene variation increases SIDS risk in African Americans
11. Americans support free access to research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ng highly precise measurements of plasma lipoprote...esonance spectroscopy (NMR), researchers led by Da...arvard Medical School in Boston, MA, the Framingha...sortium in Stockholm, Sweden and Oxford, England p...hole genome among 17,296 women of European ancestr...
(Date:11/20/2009)...A key question in the origin of biological molecul...r billions of years ago from simple precursors. No...chers in Italy have reconstructed one of the earli... of RNA from individual subunits using nothing but...A was one of the first biological molecules presen...
(Date:11/20/2009)...ssel, November 19th 2009 - Bacteria possess an ing...g the building blocks of the cell. This is the new...is Messens of VIB, a life sciences research instit...niversiteit Brussel. The scientists made this disc...rium Escherichia coli . By means of this model or...
Breaking Biology News(10 mins):Genetic analysis helps dissect molecular basis of cardiovascular disease 2Biologists discover bacterial defense mechanism against aggressive oxygen 2Global Financial Crisis a Key Driver in Market Conditions for Property Casualty and Directors and Officers Lines Says Aon 56423 1Global Financial Crisis a Key Driver in Market Conditions for Property Casualty and Directors and Officers Lines Says Aon 56423 2Global Financial Crisis a Key Driver in Market Conditions for Property Casualty and Directors and Officers Lines Says Aon 56423 3Global Financial Crisis a Key Driver in Market Conditions for Property Casualty and Directors and Officers Lines Says Aon 56423 4Global Financial Crisis a Key Driver in Market Conditions for Property Casualty and Directors and Officers Lines Says Aon 56423 5Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 1Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 2Yoga Can Ease Lower Back Pain 56417 1Yoga Can Ease Lower Back Pain 56417 2Yoga Can Ease Lower Back Pain 56417 3
...ubstances extracted from a marine seaweed may prot...w research suggests. , The animal study indicates...Ps), which are found in a type of brown marine sea... ultraviolet B (UVB) radiation. , UVB radiatio...t of the estimated 1.3 million cases of non-melano...
... role for a microRNA in the immune system has been...NA knockout mouse, reported Friday 27 April in Sci...he response of immune defences and the researchers...similar vital role. , Cells of the immune system i...cells and the mice develop symptoms similar to tho...
... team of scientists announced today confirmation o...the east coast of Greenland and in the western Bri... of global warming that raised sea surface tempera... more than six degrees in the Arctic. , The findin.... , The study is important, experts say, becaus...
Other Biology News:Chemicals in brown algae may protect against skin cancer 2Minuscule molecules pack a powerful punch 2Minuscule molecules pack a powerful punch 3Volcanic eruptions, ancient global warming linked 2Volcanic eruptions, ancient global warming linked 3
(Date:11/18/2009)..., DAVIS, Calif., Nov. 18 Marrone... development and commercialization of effective an...ucts, announced that it has been named an IC20 com...oldest and largest national angel investing group....mance leading to rewarding results for all stakeho...
(Date:11/18/2009)...ntists at Queen,s University Belfast are developin...l drugs which will help in the fight against the t...se special gel pads to ,swipe, an individual or cr...d by a scanning instrument that can detect the pre... better, faster decisions to be made in response t...
(Date:11/18/2009)..., EAST GRINSTEAD, West Sussex, U.K. and CLEVELA...s, a Magellan Biosciences business and premier pro...ducts for microbiology labs, has expanded its East...evelopment facility to meet increasing global dema...ptibility and identification testing. The expanded...
(Date:11/18/2009)... , BONITA SPRINGS, Fla., Nov. 18 /PRNewswire/ ...thanol® technology, and the technology grou...joint development project in order to identify the...ygen (O2) for Algenol,s unique algae and photobior...ompanies join forces to develop cost-efficient tec...
Breaking Biology Technology:Marrone Bio Innovations Named an IC20 Company 2New technology detects chemical weapons in seconds 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 4Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 2Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 3
...5% - Non-GAAP Operating Earnings Up 27%, GAAP Ope...EPS Up 29%, GAAP Diluted EPS Up 32%, PALO ALTO, C...y reported fourth fiscal quarter 2008 revenues of,...er revenues of $245.6,million in the fourth quarte...llent execution during the quarter. The increase i...
...n Net Revenues, $0.10 Net Income Per Share, SAN J..., Inc. (Nasdaq: VNUS ), a leading provider of med...of venous disease, today announced its,financial r...008., Net revenues for the third quarter of 2008 ... million for the third quarter of 2007. Net,revenu...
...mab Reports Results for the Nine Month Period Ende...8, COPENHAGEN, Denmark, October 29 Genmab A/S,(O...h period ended,September 30, 2008. During this per...ab,s revenues were DKK 667 million (USD 128 millio...008. In the same period of 2007, Genmab,recognized...
Other Biology Technology:Varian, Inc. Reports Strong Fourth Quarter 2008 Results 2Varian, Inc. Reports Strong Fourth Quarter 2008 Results 3Varian, Inc. Reports Strong Fourth Quarter 2008 Results 4Varian, Inc. Reports Strong Fourth Quarter 2008 Results 5Varian, Inc. Reports Strong Fourth Quarter 2008 Results 6Varian, Inc. Reports Strong Fourth Quarter 2008 Results 7Varian, Inc. Reports Strong Fourth Quarter 2008 Results 8Varian, Inc. Reports Strong Fourth Quarter 2008 Results 9Varian, Inc. Reports Strong Fourth Quarter 2008 Results 10Varian, Inc. Reports Strong Fourth Quarter 2008 Results 11Varian, Inc. Reports Strong Fourth Quarter 2008 Results 12Varian, Inc. Reports Strong Fourth Quarter 2008 Results 13Varian, Inc. Reports Strong Fourth Quarter 2008 Results 14Varian, Inc. Reports Strong Fourth Quarter 2008 Results 15Varian, Inc. Reports Strong Fourth Quarter 2008 Results 16Varian, Inc. Reports Strong Fourth Quarter 2008 Results 17Varian, Inc. Reports Strong Fourth Quarter 2008 Results 18Varian, Inc. Reports Strong Fourth Quarter 2008 Results 19Varian, Inc. Reports Strong Fourth Quarter 2008 Results 20Varian, Inc. Reports Strong Fourth Quarter 2008 Results 21Varian, Inc. Reports Strong Fourth Quarter 2008 Results 22Varian, Inc. Reports Strong Fourth Quarter 2008 Results 23Varian, Inc. Reports Strong Fourth Quarter 2008 Results 24Varian, Inc. Reports Strong Fourth Quarter 2008 Results 25Varian, Inc. Reports Strong Fourth Quarter 2008 Results 26Varian, Inc. Reports Strong Fourth Quarter 2008 Results 27VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 3VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 4VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 5VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 6VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 7VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 8VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 9VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 10
...ty Laboratory Osmometer for both 0.2 and 2.0 mL sa... built-in printer, keypad, and software for statis...ng capability with optional scanner. RS-232 port. ...tep Calibration. ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20* from Molecular Probes (Invitrogen)
Rabbit Anti-Human SCNN1A Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rat Anti-Mouse F4 / 80 Antigen Monoclonal Antibody, Biotin Conjugated from AbD Serotec
Biology Products: